$HIMS

Hims & Hers Health reported Q2 revenue of $753.2M versus $699M estimates and adjusted EBITDA of $60.32M versus $47.26M, but adjusted EPS was -$0.09 versus $0.11. The company lifted full-year revenue guidance to $3.2B and EBITDA guidance to $300M midpoint. Shares fell over 5% amid higher operating expenses and litigation costs, while management cited AI-driven customer acquisition and Eucalyptus integration.

Hinge Health will acquire Cylinder Health for $105M to expand its digital health services into gastrointestinal care. The article also notes Hackensack Meridian Health received the Joint Commission’s AI certification, and Shandong HiTHIUM launched an LDES industrial park in China. It cites U.S. wind and solar up 10% in H1 2026 and mixed Wall Street views on Circle.

Hims & Hers Health (HIMS) rose about 6% intraday before closing up 1.33% after Barclays upgraded its outlook. Barclays raised its HIMS price target to $39 from $29 and kept an Overweight rating, citing accelerating growth tied to Hims & Hers’ Novo Nordisk (NVO) partnership announced March 9. Barclays expects revenue and EBITDA acceleration in 2H 2026.

U.S. stock index futures slipped overnight after President Trump said the Iran ceasefire is on “massive life support,” ahead of his China visit. Dow Jones futures -0.04%, S&P 500 futures -0.07%, Nasdaq 100 futures -0.14%. ETFs SPY and QQQ were down, DIA up. HIMS fell post Q1 miss, QUBT rose on revenue about $3.7M, GSIT jumped on results and a $2M Army contract, AG tracked silver strength.

U.S. stock futures eased after a strong H1 rally, with Dow up about 8.9%, S&P 500 up 9.6%, Nasdaq up 12.8%, and Russell 2000 up about 22%. Traders look ahead to ADP and Thursday’s nonfarm payrolls for Fed signals. Several stocks moved premarket: NKE -4%, TSLA deliveries ~410k expected, NIO -4%, MU -4%, LUNR +8%, ASTS +20%, CVKD -16%.

Hims & Hers Health (NYSE:HIMS) shares fell over 6% after it reported Q2 revenue up 38% to $753.2M and subscribers up 19% to 2.89M. Monthly revenue per average subscriber rose 21% to $92. Full-year revenue guidance was raised to $3.1B-$3.3B. Net loss was $86.3M (37c/share) vs profit a year earlier, with gross margin down to 64% from 76%.

Canadian TSX futures were flat as investors weighed U.S.-Iran peace progress and awaited U.S. inflation data. The TSX ended Monday at 36,458.33. Barrick appointed Sebastiaan Bock CEO of its Rest of World division; shares fell 6.5% after Q2 profit missed estimates. Intel raised a common offering to $20B. Hims & Hers cut full-year EBITDA outlook and reported a Q2 net loss.

Hims & Hers Health (HIMS) reported Q2 revenue up about 40% to $753M, beating the $730.1M consensus, but adjusted EBITDA fell to $60.3M and it posted an $86M net loss. The company raised 2026 revenue guidance to $3.1B-$3.3B and expects Q3 revenue of $880M-$900M. It said it has $225M unused buyback capacity.

Hims & Hers Health, Inc. reported Q2 2026 progress driven by a March shift to expanded branded weight loss offerings and the Eucalyptus acquisition, which adds international markets above a $100M annual run rate. Management said AI handles 80% of weight-loss questions, plans injectable and oral TRT by year-end, and expects adjusted EBITDA to step up in H2 2026.

U.S. indexes fell for a second day ahead of the July CPI report. The S&P 500, Nasdaq, and Dow closed down 0.3%, 0.6%, and 0.3%. WTI rose 1.6% to about $83.50 and Brent to $89.15. Alphabet (GOOGL) led declines, while Sea Limited (SE) gained 14% on Q2 results; Riot Platforms (RIOT) rose on a reported $9.1B deal with Anthropic.